Baptisia root

Free to every reader. The safety section of every monograph is open to everyone, signed in or not. In an emergency call 000. For poisoning, call the Poisons Information Centre on 13 11 26.

15. Safety

15.1 Adverse effects in trials. The manufacturer’s review reports only mild to moderate adverse events at a rare frequency in the three GCP trials of the three-herb product, none serious [16]. In post-marketing data from 1999–2003 it counts 63 adverse-reaction reports against an estimated 12.2 million patients treated, most of them skin rashes, and one serious case (Löfgren’s syndrome) judged unlikely to be related [16]. Taw and colleagues note photosensitivity and gastrointestinal symptoms such as nausea with the product [17]. Barrett’s account of the 1999 trial records no serious adverse events and that of the 1984 study none at all [42]. These figures concern the combination, come mostly from the manufacturer, and give no Baptisia-specific adverse-effect rate. Causality for any single ingredient cannot be assessed from them.

Australian spontaneous reports. The TGA’s Database of Adverse Event Notifications (DAEN – medicines), data to 24/09/2026, searched in October 2026, holds four reports naming a Baptisia product, each with it as the single suspected medicine and none with a fatal outcome [48]. One names MediHerb Baptisia alone (an adult aged 18–64; vertigo, ataxia and abnormal coordination). Three name Esberitox N, the three-herb tablet (reaction terms across the three: anaphylactic reaction, swollen tongue, asthma, pruritus and urticaria). The public view gives no dose, preparation detail, date of onset or outcome, and the DAEN states that inclusion does not mean the event was confirmed or caused by the medicine. The Esberitox reports fit the allergic and skin reactions that dominate the manufacturer’s post-marketing data [16] and the label caution on Echinacea allergy [42]. The single MediHerb report is neurological; with the cytisine content of the root unmeasured, it is noted here and not interpreted further. Causality was not assessed (no case detail is public).

15.2 Effects of large doses (historical). "Large doses are dangerous, acting as an emeto-cathartic. Sometimes this action is so violent as to produce gastro-enteritis. Large doses have caused an excessive flow of viscid saliva, ulceration of the pharynx, insomnia, restlessness, and ocular disturbances" [10]. Ellingwood: "In poisonous doses there is an acceleration of respiration and reflex activity followed by death from central paralytic asphyxia" [13]. The young shoots, eaten as greens in New England, purged when too far grown [10,12]. Chevallier notes that Baptisia can occasionally cause nausea and vomiting [11]. Hoffmann states that no side effects or interactions have been reported at his dose of 1 mL of 1:5 tincture three times a day [3].

15.3 Case reports. A 2015 case report of Baptisia poisoning in the Journal of Emergency Medicine, and a 2016 letter in the same journal on the botanical identity of the plant involved, are being obtained in full text; they are not described here until read, and causality will be assessed (WHO-UMC) on the full reports for version 1.1. Until then the historical accounts in 15.2 are the only descriptions of poisoning we have read.

15.4 Contraindications and cautions. Grades: clinical (human data), historical (recorded clinical observation, pre-modern), expert opinion (a practitioner or manufacturer statement without stated data), theoretical (inferred from chemistry or pharmacology).

Medicine position on pregnancy and breastfeeding. Do not use Baptisia root in pregnancy or while breastfeeding. The root contains cytisine, a nicotine-like alkaloid [18], in an amount no one has measured; large doses are emetic and purgative [10]; and no human data exist, because the controlled trials of the three-herb product excluded pregnant and breastfeeding women [42] and Mills and colleagues’ evidence-based reference on herbs in pregnancy and lactation has no entry for Baptisia [43]. The manufacturer asks for professional supervision [2]; Chevallier and a conservative veterinary compilation say avoid it [11,22]. The position is precautionary and graded theoretical; it will be revisited if a measured cytisine content or human data appear.

15.5 Herb–drug interactions. No interaction study exists for Baptisia root. MediHerb refers users to its general herb–drug interaction chart [2], which was not read for this edition.

No interaction is graded above "theoretical" for Baptisia root itself.

15.6 Regulatory safety position in Australia. BAPTISIA TINCTORIA is a permissible ingredient (item 764) with no specific requirements, for purposes A and H [4]. The Poisons Standard (June 2026) lists cytisine in Schedule 3 (divided oral and oromucosal preparations with a recommended daily dose of 9 mg or less, as an aid to withdrawal from tobacco smoking in adults) and in Schedule 4 otherwise, and sparteine in Schedule 4 [5]. Section 7 of the Standard provides that a reference to a substance includes that substance "prepared from natural sources or artificially" [5]. Whether that reaches a whole-root extract in which cytisine is a minor constituent is a regulatory question for the TGA and Legal; the TGA’s listing of the plant without conditions suggests it has not treated Baptisia as a cytisine preparation. AIP comment: that is our reading, not advice. TGA safety alerts and DAEN. The searches that could not be completed in September 2026 were completed in October 2026 [48]. The TGA website search, which covers safety alerts, advisories, recalls and media releases, returned for "baptisia" only the two ARTG entries in section 12, for "esberitox" those two and the 2021 cancellation of ESBERITOX N, and for "wild indigo" nothing; a control term with a known 2026 safety alert returned that alert. No TGA safety alert, advisory or recall for Baptisia or the three-herb product was found. The DAEN search found the four reports set out in 15.1; the control term "echinacea" returned reports as expected, and "indigo" matched only the dye indigo carmine.

15.7 Children and older people. No safety data for Baptisia root in either group. No practitioner source read gives a paediatric dose of the root. The US label of the three-herb tablets gives 1 tablet three times a day at 7 years and under, 2 tablets from 8 to 12 years, and the adult dose over 12 years [42]; that is a manufacturer’s dose for the combination, not evidence of safety for Baptisia. Given the narrow dose range and the unknown cytisine content, Medicine advises against Baptisia root for children under 12 unless prescribed by a degree-qualified herbalist with competencies and adequate training in pharmacognosy.

15.8 Overdose. Expected: vomiting, purging, salivation, and at toxic doses convulsions and respiratory failure [10,13,18]. Treatment is supportive. Anyone who has swallowed a large amount of the root or extract needs emergency care; in Australia the Poisons Information Centre is on 13 11 26.

Referral. Anyone thinking of taking Baptisia root should consult a degree-qualified herbalist with competencies and adequate training in pharmacognosy.